Dr. Gershenwald is a member of the Speakers Bureau for Schering-Plough.
Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease
Article first published online: 4 MAR 2008
Copyright © 2008 American Cancer Society
Volume 112, Issue 9, pages 2030–2037, 1 May 2008
How to Cite
Anaya, D. A., Xing, Y., Feng, L., Huang, X., Camacho, L. H., Ross, M. I., Gershenwald, J. E., Lee, J. E., Mansfield, P. F. and Cormier, J. N. (2008), Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer, 112: 2030–2037. doi: 10.1002/cncr.23399
- Issue published online: 21 APR 2008
- Article first published online: 4 MAR 2008
- Manuscript Accepted: 12 NOV 2007
- Manuscript Revised: 6 NOV 2007
- Manuscript Received: 17 SEP 2007
- National Cancer Institute Clinical Oncology Research Development Program Award. Grant Number: 5-K12-CA088084
- American Society of Clinical Oncology Career Development Award. Grant Number: 88202
- high-dose interferon;
- adjuvant therapy;
- stage III;
Evidence from randomized trials in the pre-sentinel lymph node biopsy era indicate that adjuvant treatment with high-dose interferon-α (IFN) increases recurrence-free survival (RFS) in patients with high-risk melanoma. However, to the authors' knowledge, the role of this treatment in selected patients with early stage III disease has not been well studied.
The clinical and pathologic characteristics of 486 patients undergoing surgical treatment for stage III melanoma were evaluated and the authors compared outcomes for those given adjuvant treatment with IFN with those patients who had surgery alone. A particular focus was on the effect of IFN therapy on RFS and overall survival (OS) among those patients with stage IIIA disease.
The median follow-up for the entire cohort was 5.2 years; the 5-year RFS and OS rates for the entire group were 41% and 53%, respectively. Adjuvant IFN was given to 141 patients (29%). On multivariate analysis, IFN was found to be the only independent predictor for RFS in patients with stage IIIA disease (hazards ratio of 0.4; 95% confidence interval, 0.2–0.9 [P = .02]). IFN was not found to be associated with increased RFS in patients with more advanced lymph node disease (stage IIIB and stage IIIC). IFN appeared to have no effect on OS in any patient with stage III disease.
Adjuvant treatment with IFN improves RFS in melanoma patients with early stage III disease. The results of the current study should help guide management when considering adjuvant treatment for these patients. Cancer 2008. © 2008 American Cancer Society.